Joint with: Nucleic Acid Therapeutics and Targeted Delivery
Precision Genome Engineering: From Basic Mechanisms to Application
Mar 09–12, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Jonathan S. Weissman, Cecilia Cotta-Ramusino, and Joseph Bondy-Denomy
×
-
Mar 09–12, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Jonathan S. Weissman, Cecilia Cotta-Ramusino, and Joseph Bondy-Denomy
Jonathan S. Weissman, PhD
Whitehead Institute, HHMI, and MIT
Jonathan Weissman, Ph.D., is a Professor of Biology at MIT, a core member of the Whitehead Institute, Investigator at the Howard Hughes Medical Institute and member of the National Academy of Sciences. He is a pioneer in the development of next-generation CRISPR-based tools, particularly those enabling precise control of gene expression through epigenetic modulation. His work hastransformed functional genomics by enabling genome-wide perturbation screens that illuminate fundamental biology and disease mechanisms. He also has pioneered efforts to generate datasets that inform AI models in biology.
Cecilia Cotta-Ramusino, PhD
Tessera Therapeutics
Cecilia Cotta-Ramusino, Ph.D., was one of the founding scientists at Editas Medicine and currently leads platform development at Tessera Therapeutics. She has been instrumental in advancing therapeutic genome engineering platforms, with a focus on nextgeneration programmable technologies for genome writing.
Joseph Bondy-Denomy, PhD
University of California, San Francisco
Joe Bondy-Denomy, Ph.D., is a Professor of Microbiology at UCSF and an internationally recognized expert in CRISPR-Cas biology. He made the foundational discovery of anti-CRISPR systems and has contributed extensively to understanding the mechanisms and diversity of CRISPR-based microbial defense. Dr Bondy-Denomy is a leader in the phage biology world and is a co-organizer of two other upcoming meetings in 2025-2026 on bacteriophages and bacteriophage defense systems.
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMonday, March 9, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Tuesday, March 10, 2026
Breakfast
7:00–8:00 AM
President's Hall
Welcome Remarks (Joint)
8:00–8:10 AM
Van Horne A/B
Keynote Session (Joint)
8:10–9:00 AM
Van Horne A/B
Jennifer A. Doudna, HHMI/University of California, Berkeley
CRISPR Enzyme Evolution and Applications
CRISPR Enzyme Evolution and Applications
Delivery (Joint)
9:00–11:00 AM
Van Horne A/B
Daniel J. Siegwart, University of Texas Southwestern Medical Center
New LNP Modalities for Target Lung, Heart and Other Tissues
New LNP Modalities for Target Lung, Heart and Other Tissues
Michael A. Fischbach, Stanford University
Engineered Viral-Like Particle for Targeted Delivery of Gene Editors
Engineered Viral-Like Particle for Targeted Delivery of Gene Editors
Leah R Sabin, Regeneron Pharmaceuticals
Antibody-AAV Targeting: Fundamental Principle Behind Achieving BBB Crossing
Antibody-AAV Targeting: Fundamental Principle Behind Achieving BBB Crossing
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Van Horne A/B
Poster Setup
11:00–1:00 PM
Van Horne C
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Symposia Spotlight 1
2:30–4:30 PM
Van Horne A
Clare Cahir, The Rockefeller University
Cap1 Forms a Cyclic Tetra-adenylate-induced Membrane Pore during the Type III-A CRISPR-Cas Immune Response
Cap1 Forms a Cyclic Tetra-adenylate-induced Membrane Pore during the Type III-A CRISPR-Cas Immune Response
Chris J Frangieh, Columbia University Medical Center
Resolving Ambiguity from Variants of Uncertain Significance by Linking Variants, Phenotype, and Allele-specific Expression Bias in Inborn Errors of Immunity
Resolving Ambiguity from Variants of Uncertain Significance by Linking Variants, Phenotype, and Allele-specific Expression Bias in Inborn Errors of Immunity
Bria Macklin †, Gladstone Institutes
Mutation Agnostic CRISPR Therapeutics to Treat Dominant Neurodegenerative Disease
Mutation Agnostic CRISPR Therapeutics to Treat Dominant Neurodegenerative Disease
Bushra Raj, University of Pennsylvania
High throughput in vivo Mapping of Signaling Histories with CRISPR Barcodes
High throughput in vivo Mapping of Signaling Histories with CRISPR Barcodes
Shengdar Q Tsai, St. Jude Children's Research Hospital
High-throughput Biochemical and Cellular Approaches towards Developing a CRISPR Therapeutic Genome Editing Platform
High-throughput Biochemical and Cellular Approaches towards Developing a CRISPR Therapeutic Genome Editing Platform
Christopher Baehr, UC Berkeley
Chemically Modified CRISPR Enzymes for Multi-organ Genome Editing in vivo
Chemically Modified CRISPR Enzymes for Multi-organ Genome Editing in vivo
Wayne Ngo, University of California, Berkeley
Amplifying Editing Efficiencies by Making Genome Editing Vesicles in the Body
Amplifying Editing Efficiencies by Making Genome Editing Vesicles in the Body
Wells Burrell, New York Genome Center
Rational Design of Synthetic Proteins Using a Genome-Scale CRISPR Screen
Rational Design of Synthetic Proteins Using a Genome-Scale CRISPR Screen
Coffee Available
4:30–5:00 PM
Van Horne Foyer
New Editing Modality
5:00–7:00 PM
Van Horne A
Samuel H Sternberg, Columbia University
CRISPR Guided Transposons
CRISPR Guided Transposons
Cecilia Cotta-Ramusino, Tessera Therapeutics
Discovery and Application of New Gene Editing Modalities to Treat Disease
Discovery and Application of New Gene Editing Modalities to Treat Disease
Erik J Sontheimer †, University of Massachusetts Medical School
Short Talk: Prime Assembly with Linear DNA Donors Enables Large Genomic Insertions
Short Talk: Prime Assembly with Linear DNA Donors Enables Large Genomic Insertions
Social Hour with Dinner
7:00–8:00 PM
President's Hall
Poster Session 1
7:30–10:00 PM
Van Horne C
Wednesday, March 11, 2026
Breakfast
7:00–8:00 AM
President's Hall
Understanding and Therapeutic Application of CRISPR
8:00–11:00 AM
Van Horne A
Emma Wang, YolTech Therapeutics
Design of Therapeutic Editors Aided by AI and High Throughput Approaches
Design of Therapeutic Editors Aided by AI and High Throughput Approaches
Xiao Wang, University of Pennsylvania
Developing Bespoke Gene Editing Treatments for Patients with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency in Real Time: Successes and Challenges
Developing Bespoke Gene Editing Treatments for Patients with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency in Real Time: Successes and Challenges
Britt Adamson, Princeton University
DNA Damage Response and CRISPR
DNA Damage Response and CRISPR
Benjamin P. Kleinstiver, Massachusetts General Hospital
Engineered Technologies for Modifying Single Bases to Several Kilobases
Engineered Technologies for Modifying Single Bases to Several Kilobases
Gerald Schwank, University Zurich
Short Talk: Rescue of Monogenic Obesity by In Vivo Base and Prime Editing in the Brain
Short Talk: Rescue of Monogenic Obesity by In Vivo Base and Prime Editing in the Brain
Dowoon Gu †, Korea University
Short Talk: Combination of Abasic Substitution and Extension in Guide RNA Inherently Harness Fidelity of SpCas9 for Genome Editing
Short Talk: Combination of Abasic Substitution and Extension in Guide RNA Inherently Harness Fidelity of SpCas9 for Genome Editing
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Van Horne C
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Career Roundtable (Joint)
3:00–4:30 PM
Van Horne B
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Intersection of Gene Editing High Throughput Screening and Machine Learning
5:00–7:00 PM
Van Horne A
Hyongbum Henry Kim, Yonsei University College of Medicine
Experimental and Machine Learning Approaches to Create New Genome Editing Tools
Experimental and Machine Learning Approaches to Create New Genome Editing Tools
Jonathan S. Weissman, Whitehead Institute, HHMI, and MIT
In vivo Multiple Modal Information-Rich CRISPR Screens
In vivo Multiple Modal Information-Rich CRISPR Screens
Randall J. Platt, ETH Zurich
Functional Genomic Approaches
Functional Genomic Approaches
Charles Gersbach, Duke University
Short Talk: Cell Reprogramming by CRISPR-based Activation of Endogenous Master Transcription Factors
Short Talk: Cell Reprogramming by CRISPR-based Activation of Endogenous Master Transcription Factors
Noa Oded Elkayam, EmendoBio
Short Talk: AI-Enhanced Optimization of OMNI Nucleases Expands the CRISPR Toolbox for Therapeutic Applications
Short Talk: AI-Enhanced Optimization of OMNI Nucleases Expands the CRISPR Toolbox for Therapeutic Applications
Social Hour with Dinner
7:00–8:00 PM
President's Hall
Poster Session 2
7:30–10:00 PM
Van Horne C
Thursday, March 12, 2026
Breakfast
7:00–8:00 AM
President's Hall
Therapeutic Application
8:00–11:00 AM
Van Horne A
Jennifer Gori, Prime Medicine, Inc.
Application of Prime Editing to Treat Disease
Application of Prime Editing to Treat Disease
Haihua Chu, Beam Therapeutics
Unlocking the Potential of base Edited HSCs for Therapeutic Applications with Epitope Engineering
Unlocking the Potential of base Edited HSCs for Therapeutic Applications with Epitope Engineering
Laura Sepp-Lorenzino, Intellia Therapeutics
TTR Therapies
TTR Therapies
Luigi M Naldini, San Raffaele Telethon Institute for Gene Therapy
Gene Editing: Therapeutics and Genotoxicity
Gene Editing: Therapeutics and Genotoxicity
X. Shawn Liu, Columbia University Medical Center
Short Talk: Epigenetic Silencing of Pathological Allele in Inborn Errors Immunity by CRISPR-IMPRINT
Short Talk: Epigenetic Silencing of Pathological Allele in Inborn Errors Immunity by CRISPR-IMPRINT
Sarah Pierce, Broad Institute
Short Talk: Prime Editing-installed Suppressor tRNAs for Disease-Agnostic Genome Editing
Short Talk: Prime Editing-installed Suppressor tRNAs for Disease-Agnostic Genome Editing
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2
2:30–4:30 PM
Van Horne A
Shirley P Chia, National University of Singapore
Variant-By-Variant Activity Profiling Reprograms A CRISPR-Associated Transposon Towards Precise DNA Insertion
Variant-By-Variant Activity Profiling Reprograms A CRISPR-Associated Transposon Towards Precise DNA Insertion
Phoebe A Rice, University of Chicago
Structural Basis for Directionality of Large Serine Integrases
Structural Basis for Directionality of Large Serine Integrases
Sébastien Levesque, Boston Children's Hospital - Harvard Medical School
In Cellulo DNA Assembly for Targeted Genomic Integration and Rearrangement in Human Cells
In Cellulo DNA Assembly for Targeted Genomic Integration and Rearrangement in Human Cells
Shannon M Miller, Scripps Research
Programmable CRISPR-free gene insertion
Programmable CRISPR-free gene insertion
Holt A Sakai, Broad Institute
Directed Evolution of Small RNA-stabilizing Motifs that Improve Prime Editing
Directed Evolution of Small RNA-stabilizing Motifs that Improve Prime Editing
Lilly van de Venn, ETH Zurich
AutoDISCO Enables Sensitive and High-throughput CRISPR/Cas Off-target Detection in Cells and Organisms
AutoDISCO Enables Sensitive and High-throughput CRISPR/Cas Off-target Detection in Cells and Organisms
Kah Min Yap, Peter MacCallum Cancer Centre
Rewiring Endogenous Genes in CAR T Cells for Tumour-Restricted Payload Delivery
Rewiring Endogenous Genes in CAR T Cells for Tumour-Restricted Payload Delivery
Aditya V Ansodaria, UMass Chan Medical School
Enhancing the Efficacy and Purity of Prime Editing using Chemically Modified Editing Templates and Modification-Tolerant Polymerases
Enhancing the Efficacy and Purity of Prime Editing using Chemically Modified Editing Templates and Modification-Tolerant Polymerases
Coffee Available
4:30–5:00 PM
Van Horne Foyer
CRISPR Biology
5:00–6:45 PM
Van Horne A
Joseph Bondy-Denomy, University of California, San Francisco
AntiCRISPR Phage Defense Against CRISPR Systems
AntiCRISPR Phage Defense Against CRISPR Systems
Mitchell R. O'Connell, University of Rochester Medical Center
Pulling the Plug on Bacteriophage Infection: The Pore Behavior of CRISPR and Anti-phage Defense Associated Membrane Proteins
Pulling the Plug on Bacteriophage Infection: The Pore Behavior of CRISPR and Anti-phage Defense Associated Membrane Proteins
Elizabeth Kellogg, St. Jude Children's Research Hospital
Mechanism of Programmable Transposases
Mechanism of Programmable Transposases
Kazuo Nakamura, Gladstone Institutes
Short Talk: Phage Defense and Genome Editing using Novel Retrons Sourced from Isolated Environmental Bacteria
Short Talk: Phage Defense and Genome Editing using Novel Retrons Sourced from Isolated Environmental Bacteria
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
Van Horne A
Social Hour with Dinner
7:00–8:00 PM
President's Hall
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Friday, March 13, 2026
Departure
12:00–11:59 PM
Subscribe for Updates